27876598|t|Antithrombotic activity of Batroxase, a metalloprotease from Bothrops atrox venom, in a model of venous thrombosis
27876598|a|Snake venoms are great sources of bioactive molecules, which may be used as models for new drugs. Toxins that interfere in hemostasis have received considerable attention over the years. This study aimed at the evaluation of the antithrombotic activity of Batroxase, a P-I metalloprotease from Bothrops atrox venom, in an animal model of venous thrombosis. The antithrombotic activity of Batroxase was tested in vivo in a model based on two factors of the Virchow's Triad: blood flow alterations (partial stenosis of the inferior vena cava), and vessel wall injury (10% ferric chloride for 5min), in comparison with sodium heparin (positive control) and saline (negative control). Bleeding / clotting time was assessed by a tail bleeding assay. The immunogenicity of Batroxase was also analyzed. Batroxase (12mg/kg) reduced thrombus formation in 81%, similarly to heparin (100U/kg), which reduced it in 85% in comparison with the saline group. Both Batroxase and heparin increased bleeding / clotting time in approximately 3 fold. Immunizations of rabbits with Batroxase do not result in detectable levels of antibodies against this metalloprotease. Batroxase presents antithrombotic activity in vivo. Moreover, its lack of immunogenicity increases the interest on its possible therapeutic potential over thrombogenic disorders.
27876598	0	23	Antithrombotic activity	T033	UMLS:C0243095
27876598	27	36	Batroxase	T103	UMLS:C4278231
27876598	40	55	metalloprotease	T103	UMLS:C0025543
27876598	61	81	Bothrops atrox venom	T103	UMLS:C4033446
27876598	88	93	model	T204	UMLS:C0599779
27876598	97	114	venous thrombosis	T038	UMLS:C0042487
27876598	115	127	Snake venoms	T103	UMLS:C0037380
27876598	191	197	models	T170	UMLS:C3161035
27876598	206	211	drugs	T103	UMLS:C0013227
27876598	213	219	Toxins	T103	UMLS:C0040549
27876598	238	248	hemostasis	T038	UMLS:C0005779
27876598	307	312	study	T062	UMLS:C2603343
27876598	344	367	antithrombotic activity	T033	UMLS:C0243095
27876598	371	380	Batroxase	T103	UMLS:C4278231
27876598	384	403	P-I metalloprotease	T103	UMLS:C0025543
27876598	409	429	Bothrops atrox venom	T103	UMLS:C4033446
27876598	437	449	animal model	T204	UMLS:C0599779
27876598	453	470	venous thrombosis	T038	UMLS:C0042487
27876598	476	499	antithrombotic activity	T033	UMLS:C0243095
27876598	503	512	Batroxase	T103	UMLS:C4278231
27876598	524	531	in vivo	T082	UMLS:C1515655
27876598	537	542	model	T204	UMLS:C0599779
27876598	571	586	Virchow's Triad	T170	UMLS:C0282574
27876598	588	598	blood flow	T038	UMLS:C0232338
27876598	612	628	partial stenosis	T017	UMLS:C0333183
27876598	636	654	inferior vena cava	T017	UMLS:C0042458
27876598	661	672	vessel wall	T017	UMLS:C0229962
27876598	673	679	injury	T037	UMLS:C0178314
27876598	685	700	ferric chloride	T103	UMLS:C0060229
27876598	731	745	sodium heparin	T103	UMLS:C0037513
27876598	796	804	Bleeding	T201	UMLS:C0550585
27876598	807	820	clotting time	T033	UMLS:C2266672
27876598	844	858	bleeding assay	T038	UMLS:C0019080
27876598	864	878	immunogenicity	T038	UMLS:C1148560
27876598	882	891	Batroxase	T103	UMLS:C4278231
27876598	911	920	Batroxase	T103	UMLS:C4278231
27876598	939	957	thrombus formation	T033	UMLS:C0243095
27876598	979	986	heparin	T103	UMLS:C0019134
27876598	1064	1073	Batroxase	T103	UMLS:C4278231
27876598	1078	1085	heparin	T103	UMLS:C0019134
27876598	1096	1104	bleeding	T201	UMLS:C0550585
27876598	1107	1120	clotting time	T033	UMLS:C2266672
27876598	1146	1159	Immunizations	T058	UMLS:C0020971
27876598	1163	1170	rabbits	T204	UMLS:C3887509
27876598	1176	1185	Batroxase	T103	UMLS:C4278231
27876598	1224	1234	antibodies	T103	UMLS:C0003241
27876598	1248	1263	metalloprotease	T103	UMLS:C0025543
27876598	1265	1274	Batroxase	T103	UMLS:C4278231
27876598	1284	1307	antithrombotic activity	T033	UMLS:C0243095
27876598	1308	1315	in vivo	T082	UMLS:C1515655
27876598	1339	1353	immunogenicity	T038	UMLS:C1148560
27876598	1420	1442	thrombogenic disorders	T038	UMLS:C0012634